Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 11fludarabine phosphate 10Rituximab 6Peripheral Blood Stem Cell Transplantation 6Cytarabine 6fludarabine 5Vincristine 4Radiotherapy 4Etoposide 4Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Filgrastim 3tisagenlecleucel 2blinatumomab 2Vorinostat 2Prednisone 2Pentetic Acid 2Methylprednisolone 2Melphalan 2Drug Therapy 2Doxorubicin 2Cord Blood Stem Cell Transplantation 2Carmustine 2CT-P10 2Busulfan 2Bortezomib 2Biopsy 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Burkitt Lymphoma × Liposomes × Clear all
NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Children's Oncology Group

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡